|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport decreases activity multiple interactions |
ISO |
ABCG2 protein affects the transport of oxfendazole oxfendazole results in decreased activity of ABCG2 protein oxfendazole inhibits the reaction [ABCG2 protein affects the transport of Mitoxantrone] |
CTD |
PMID:15703302 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA] |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
EXP |
oxfendazole results in increased cleavage of CASP3 protein |
CTD |
PMID:26558467 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
oxfendazole results in increased expression of CDKN1A protein |
CTD |
PMID:26558467 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek1 |
checkpoint kinase 1 |
affects expression |
EXP |
oxfendazole affects the expression of CHEK1 mRNA |
CTD |
PMID:26558467 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 protein; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of CYP1A2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP1A2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of CYP2B2 mRNA] |
CTD |
PMID:20033131 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GPX2 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GPX2 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[isoquercitrin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [Melatonin co-treated with oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of GSTM1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of GSTM1 mRNA |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
EXP |
oxfendazole results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:26558467 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases phosphorylation increases expression |
EXP |
oxfendazole results in decreased phosphorylation of MDM2 protein oxfendazole results in increased expression of MDM2 mRNA |
CTD |
PMID:26558467 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of ME1 mRNA; isoquercitrin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA]; Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of ME1 mRNA] |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
oxfendazole results in decreased expression of MKI67 protein |
CTD |
PMID:26558467 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole co-treated with Melatonin] results in increased expression of NQO1 mRNA; [Diethylnitrosamine co-treated with oxfendazole] results in increased expression of NQO1 mRNA; [oxfendazole co-treated with Diethylnitrosamine] results in increased expression of NQO1 mRNA |
CTD |
PMID:18754104 PMID:20033131 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
oxfendazole inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
EXP |
oxfendazole results in decreased expression of TOP2A protein |
CTD |
PMID:26558467 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
oxfendazole results in decreased expression of TP53 mRNA |
CTD |
PMID:26558467 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|